BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35217907)

  • 1. Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.
    Wong C; Chu P; Teoh J; Chiu P; Yee CH; Chau L; Chan M; Wan H; Leung S; Ng CF
    Int Urol Nephrol; 2022 May; 54(5):993-1000. PubMed ID: 35217907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
    Wong CHM; Xu N; Lim J; Feng KK; Chan WKW; Chan MTY; Leung SC; Chen DN; Lin YZ; Chiu PKF; Yee CH; Teoh JYC; Huang CY; Yeoh WS; Ong TA; Wei Y; Ng CF
    Prostate; 2023 Jun; 83(8):801-808. PubMed ID: 36938957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data.
    Gomaa S; Kelly WK; Mitchell E; Storozynsky E; Zeigler-Johnson C; Juon HS; Wen KY
    World J Urol; 2023 Sep; 41(9):2351-2357. PubMed ID: 37555986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
    Lee YHA; Hui JMH; Chan JSK; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
    Prostate; 2023 Jan; 83(1):119-127. PubMed ID: 36178848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
    Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
    Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
    Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
    J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
    Lee YHA; Hui JMH; Chung CT; Liu K; Dee EC; Ng K; Tse G; Chan JSK; Ng CF
    Cancer Med; 2023 Apr; 12(8):9128-9132. PubMed ID: 36734312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
    Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.
    Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
    BJU Int; 2015 Sep; 116(3):382-7. PubMed ID: 25327618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
    Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
    Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.
    Sun L; Parikh RB; Hubbard RA; Cashy J; Takvorian SU; Vaughn DJ; Robinson KW; Narayan V; Ky B
    JAMA Netw Open; 2021 Feb; 4(2):e210070. PubMed ID: 33625512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.
    Derweesh IH; Diblasio CJ; Kincade MC; Malcolm JB; Lamar KD; Patterson AL; Kitabchi AE; Wake RW
    BJU Int; 2007 Nov; 100(5):1060-5. PubMed ID: 17868420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.